AlphAIalphai — Financial news for AI agents
BenzingaOCT 212 min read$HRTX

Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Heron Therapeutics (NASDAQ:HRTX)

CARY, N.C., Oct. 21, 2025 ( GLOBE NEWSWIRE ) -- Heron Therapeutics, Inc. ( NASDAQ:HRTX ) ( "Heron" or the "Company" ) , a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Tuesday, November 4, 2025, at 8:30 a.m.

Original reporting
Benzinga · Globe Newswire
Published Oct 21, 2025, 8:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 21, 2025, 9:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 - Heron Therapeutics (NASDAQ:HRTX) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$HRTXBullishMed
01

Why it matters

The upcoming earnings report is likely to be the primary driver of short-term stock price movements, with market sentiment leaning towards cautious optimism.

02

Market read

The news is highly relevant for traders and investors interested in biotech stocks, especially those with exposure to HRTX.

03

What to watch

Potential regulatory issues or unforeseen negative news could negate positive earnings impact.

Timing: High; the earnings report date (November 4, 2025) is imminent.

Background

Heron Therapeutics is a biotech company preparing to release Q3 2025 financial results, which are highly anticipated by investors.

Company-level read

Ticker impact

$HRTXBullishMedium confidence
Context

High relevance due to upcoming earnings report and recent positive sentiment.

Expected impact

Potential short-term increase in stock price leading up to and following the earnings report.

Evidence & confidence

Earnings reports often lead to increased volatility. The current sentiment indicates mild optimism, but actual results could diverge, affecting stock movement.

Market effects

Sector

Positive earnings could boost biotech sector sentiment, especially for companies with similar profiles.

Regional

Limited regional impact; primarily relevant to US markets where HRTX is listed.

Global

Moderate; biotech sector trends can influence global biotech indices but are less impactful on broader markets.

Counterpoint

What could challenge this read

Earnings could underperform expectations, leading to a sharp decline; the current positive sentiment may be overly optimistic.

Key entities

  • Company
    Heron Therapeutics, Inc.

    A biotechnology company focused on developing and commercializing therapeutics.

Read at source← All news

Related articles

AUG 10
$HRTXMedAI 8/10

Heron Therapeutics Q2 Earnings Call Highlights

Heron Therapeutics (NASDAQ:HRTX) reported Q2 sales of about $4.2M for APONVIE, up 26% QoQ and 74% YoY, and $21.8M for CINVANTI, down about 10% YoY. SUSTOL contributed $0.5M as wind-down continued. Heron posted a Q2 net loss of $5.5M, gross margin 69.3%, and ended with $42.7M cash equivalents. It amended its Hercules credit facility with a $13.5M principal reduction and potential $4M more, and withdrew 2026 guidance.

yahoo.com6 min
AUG 10
$HRTXMed

HERON THERAPEUTICS, INC. /DE/ (HRTX): Results of Operations and Financial Condition

HERON THERAPEUTICS, INC. /DE/ (HRTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 hrtx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Heron Therapeutics Announces Second Quarter 2026 Financial Results - Q2 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026; ZYNRELEF ® net revenue grew 35% and APONVIE ® net revenue grew 74% year-over-yea

SEC EDGAR 8-K6 min
AUG 10
$NVDAMed

Nvidia teams up with Wall Street asset managers on $500 billion AI infrastructure push

CNBC reports Nvidia is working with Apollo, Blackstone, BlackRock’s Global Infrastructure Partners, Brookfield, Goldman Sachs and KKR on a planned $500 billion financing push for AI infrastructure, citing an unnamed source. An announcement could come as soon as Monday, according to the report. The effort would help customers finance Nvidia GPUs and data centers, including power capacity needs.

cnbc.com4 min
AUG 10
$ARTWMed

Art's-Way Manufacturing Co.: Art's Way Announces Significant Increase in Backlog Following Award of Major Modular Building Projects

Art's-Way Manufacturing Co. (Nasdaq:ARTW) said its Modular Buildings segment backlog rose to over $19.0 million after winning major modular building projects. The company cited a prior $1.3 million backlog in its May 31, 2026 10-Q. It expects fulfillment by end of fiscal 2027, subject to schedules and milestones, with margins generally consistent with historical performance.

finanznachrichten.de3 min